P. Hemachandra Reddy, PhD | Texas Tech University Health Sciences Center

P. Hemachandra Reddy, PhD

 

Hemachandra Reddy

P. Hemachandra Reddy, PhD

Professor, Department of Internal Medicine
Professor, Neurology and Neuroscience/Pharamacology


Reddy Laboratory - Research Website
Reddy Google Scholar Link

 

P. Hemachandra Reddy, Ph.D., is the Tenured Professor and Vice Chair Research of Basic and Translational Sciences Internal Medicine and Professor of  Pharmacology & Neuroscience, Neurology, Public Health and Speech, Language and Hearing Departments at Texas Tech University Health Sciences Center in Lubbock. Dr. Reddy is also an adjunct Professor of Nutritional Sciences Department of Human Sciences at Texas Tech University, in Lubbock.

Dr. Reddy is an elected fellow of the American Neurological Association (2014), and an elected Fellow of American Association for the Advancement of Sciences (2020). Received Bharath Gaurav Award from Government of India (2016).  

He was formerly an Executive Director and Chief Scientific Officer of the Garrison Institute on Aging (2014-2019) and former Associate Scientist (2009-2014) in the Division of Neuroscience at the Oregon National Primate Research Center, affiliated with Oregon Health & Sciences University. Dr. Reddy received his B.Sc. and M.Sc. in biology from Sri Venkateswara University, Tirupati, India, and he received an M. Phil in human cytogenetics from Delhi University. As a commonwealth scholar (1990–1993), he was awarded a PhD (1994) in human genetics from the University College, London. Dr. Reddy received postdoctoral training (1995-2000) at the National Human Genome Research Institute of the National Institutes of Health. He was a standing member of the Veteran Affairs Merit Review Study Section (2007-2010), and NIH study section, Neuronal Oxidative Metabolism and Death (2013-2019) and served on several NIH study sections. He received funding from NIH since 2002. Currently he is the principal investigator to 2 NIH R01 grants, 2 R56 grants.  Dr. Reddy is the Co-inventor and Chief Scientific Officer of Lubbock-based small business company, abSynapTEX, LLC. Recently, abSynapTEX, LLC received an STTR award from NIH. 

Dr. Reddy is a prolific writer, author or co-author of more than 237 peer-reviewed articles/chapters/reviews, including publications in such journals as Nature Genetics, Redox Biology, Aging Cell, Ageing Research Reviews, Trends in Neurosciences, Trends in Molecular Medicine, Drug Discovery Today and Human Molecular Genetics. As indicated on the Google Scholar website https://scholar.google.com/citations?view_op=list_works&hl=en&user=AfziV3YAAAAJ (accessed November, 2022, Google Scholar search), Dr. Reddy’s articles have received over 24,655 citations with an H-Index of 83 and an i10-Index of 175.

He received several awards and honors including Prestigious Bharath Gaurav Award (2016) from Government of India; best mentor award (2003) and Technology innovation award (2007) from Oregon Health and Science University and Alzheimer's Award (2006) from the Journal of Alzheimer's Disease and Fellows Award for Research Excellence (FARE Award) (1999) from National Institutes of Health. Dr. Reddy was honored with best neuroscientist for his contributions to neurology and brain disorders at the second International conference, Rome, Italy June 3-6, 2018.

Dr. Reddy received two patents for his lab discoveries:  a) D-1289 - Aqua-soluble DDQ Promotes Healthy Aging and Delays Progression of Alzheimer’s Disease in Humans), b) D-1417 - MicroRNA-455-3p as a Potential Peripheral Biomarker for Alzheimer’s Disease and several others are pending, including c) D-1535 - Identification of novel circulatory microRNA signatures linked to patients with Ischemic Stroke, d) D-1294 - Mitochondrial Division Inhibitor 1 for the Treatment of Alzheimer’s Disease), e) D-1417 - MicroRNA-455-3p as a Potential Peripheral Biomarker for Alzheimer’s Disease), f) D-2019-066 - Phosphorylated Tau Inhibitors for treatment of Alzheimer's Disease” disclosed 4/8/2019, and D-2020-060 and g) BACE1 Inhibitory Ligand Molecules against Amyloid Beta-induced Synaptic and Mitochondrial Toxicities. 

He served on several review panels and committees, outside the TTUHSC, including:  a) Regular member of the NIH Neuronal Oxidative Metabolism and Death Study Section (2013-2019), b) Fellow of the American Neurological Association (2014 to present), Fellow of the American Association for the Advancement of Sciences (2020), and within TTUHSC  - a) Member of the TTUHSC Faculty Development Leave Committee (2015-2018), b) Member and Chair of the SOM-TTUHSC Research Executive Committee (2016-2019), c) Member of the TTUHSC Medical Students Promotion Committee (2016-2019), d) Member of the University Research Council (2017-2018), and e) Member of the TTUHSC Post Tenure Committee (2018-2020).

Dr. Reddy supervised/mentored over 120 interns/students/postdoctoral fellows/junior faculty.  At least 10 his postdoctoral fellows are faculty members and/or working in established pharmaceutical companies in US and abroad. Most recently, Dr. Reddy’s postdoctoral Fellow Dr. Subodh Kumar received a 5-year Career Development Award from NIA/NIH. Several others are waiting for the outcome of their Career Development Awards. 

He trained over 15 medical students in the last 6 years here at TTUHSC, these students are authors and co-authors in high impact factor journals and matched at the best residency programs in US. In 2020 alone, 6 medical students (years 1-3), were worked with Dr. Reddy in conducting research in the lab and/or writing articles. Major focus of 2020 medical students research is on COVID-19.  

Dr. Reddy strongly supports women in science and currently, the Reddy Lab has more women scientists than men scientists at all levels; postdoctoral scientists, technicians, students, and interns. We believe this is a wonderful accomplishment, and we recognize the need for more women in Science Technology, Engineering and Mathematics (STEM). Reddy and his colleagues encourage and strongly supports women in science. The Reddy lab is committed to ensuring flexibility and a encouraging environment for women in science. We ensure that our scientists can flex-out to balance work-life schedule as long they are happy and enjoy their work. Dr. Reddy and lab colleagues are proud to see a FIRST WOMEN PRESIDENT, Dr. Lori Rice-Spearman at TTUHSC. 

He recognizes that scientific and biomedical discoveries does not take place in isolation from society.  He strongly believes his lab research outcome will be useful to communities in US and across the globe. Past and current events have led us to take an active stance in examining how research in academia at large and the Reddy lab in particular can take up the work of creating a more equitable society without discrimination of sex and race.

He has over 20 years of research and leadership experience.  He enjoys teaching & researching in neurological diseases and truly believe that in his lifetime, significant therapeutic developments will improve the lives of persons with neurological diseases and their caretakers.  Dr. Reddy also enjoy managing large organizations, that led to developing and maintaining a large network of colleagues in research, education, and government regulation. 

Dr. Reddy's research interests are – Drug Discovery, Healthy Aging, MicroRNAs, Synapse, Mitochondria, Oxidative Stress, Neurodegenerative Diseases including Alzheimer's, Huntington's Parkinson's, Multiple Sclerosis, Diabetes/Obesity, Multiple Sclerosis, Depression, Gender-based Studies, Biomarker Development, Bioinformatics and Gene Expression Analysis, and Animal models.

     2021

     2019

      • Kumar S, Reddy PA, Yin X and Reddy PH. Novel microRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer’s disease. Poster presented at the Annual Meeting of Society for Neuroscience, Chicago, October 19-23, 2019.
      • Vijayan M and Reddy PH (2019) Novel microRNA PC-5P-12969 and ischemic stroke. Poster presented at the Annual Meeting of Society for Neuroscience, Chicago, October 19-23, 2019.
      • Pradeepkiran JA and Reddy PH (2019) Structure based design and molecular docking studies for phosphorylated tau inhibitors in Alzheimer’s disease. Poster presented at the Annual Meeting of Society for Neuroscience, Chicago, October 19-23, 2019.
      • Invited plenary presentation ‘Early Cellular Changes in Alzheimer’s Disease’ at the International Conference on Neurological Diseases and Therapeutics, Gandhinagar, India, organized by National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad.
      • Invited talk ‘Protective Role of Reduced Drp1 in Alzheimer’s Disease’ by Dr. Kim Tieu, Florida International University, March 28, 2019.
      • Invited talk ‘MicroRNAs as Early Detectable Biomarkers for Alzheimer’s Disease and Ischemic Stroke’ by Dr. H Lee, University of Texas, San Antonio, Feb 4, 2019.

Click here for a complete list of Dr. Reddy's presentations.

  1. John A, Kubosumi A and Reddy PH (2020) Mitochondrial MicroRNAs in Aging and Neurodegenerative Diseases. Cells. 2020 May 28;9(6):E1345. doi: 10.3390/cells9061345.
  2. Khan H, Reddy PH et al. (2020) Gender Differences in Prevalence of Myocardial Infarction in Rural West Texans. Published online May 18, Journal of Public Health, From theory to Practice.
  3. Vijayan M and Reddy PH (2020) Non-Coding RNAs Based Molecular Links in Type 2 Diabetes, Ischemic Stroke, and Vascular Dementia. Journal of Alzheimer’s Disease, J Alzheimers Dis. 2020;75(2):353-383. doi: 10.3233/JAD-200070.
  4. Bhatti G, Reddy AP, Reddy PH and Bhatti J (2019) Lifestyle modifications and nutritional interventions in aging- associated cognitive decline and Alzheimer’s disease. Frontiers in Aging Neuroscience. Front Aging Neurosci. 2020 Jan 10;11:369. doi: 10.3389/fnagi.2019.00369. eCollection 2019.
  5. Pradeepkiran JA, Reddy AP, Yin X, Manczak M, Reddy PH. Protective Effects of BACE1 Inhibitory Ligand Molecules Against Amyloid Beta-Induced Synaptic and Mitochondrial Toxicities in Alzheimer's Disease. Hum Mol Genet. 2020 Jan 1;29(1):49-69. doi: 10.1093/hmg/ddz227.
  6. Reddy PH. Current status of stem cell research: An editorial. Biochim Biophys Acta Mol Basis Dis. 2020 Apr 1;1866(4):165635. doi: 10.1016/j.bbadis.2019.165635.PubMed PMID: 31862303.
  7. Mani C, Reddy PH, Palle K. DNA repair fidelity in stem cell maintenance, health, and disease. Biochim Biophys Acta Mol Basis Dis 2020 Apr 1;1866(4):165444. doi: 10.1016/j.bbadis.2019.03.017.
  8. Reddy PH. Lifestyle and Risk Factors of Dementia in Rural West Texas. J Alzheimers Dis. 2019;72(s1):S1-S10. doi: 10.3233/JAD-191280. PubMed PMID: 31884491.
  9. Khan H, Rafiq A, Shabaneh O, Gittner L and Reddy PH (2019) Current Issues in Chronic Diseases: A Focus on Dementia and Hypertension in Rural West Texans. J Alzheimers Dis. 2019;72(s1):S59-S69. doi: 10.3233/JAD-190893.
  10. Hegde V, Dhurandhar N and Reddy PH (2019) Hyperinsulinemia or Insulin Resistance. What Impacts the progression of Alzheimer's Disease. J Alzheimers Dis. 2019;72(s1):S71-S79. doi: 10.3233/JAD-190808.
  11. Sawant N and Reddy PH (2019) Role of Phosphorylated Tau in Huntington’s Disease Progression J Alzheimers Dis. 2019;72(s1):S177-S191. doi: 10.3233/JAD-190851.
  12. Hegde V, Vijayan M, Kumar S, Akheruzzaman M, Sawant N, Dhurandhar NV, Reddy PH. Adenovirus 36 improves glycemic control and markers of Alzheimer's disease pathogenesis. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(11):165531. doi: 10.1016/j.bbadis.2019.08.007.
  13. Kim Y, Gonzales JU, Reddy PH. An Investigation of Short-Term Longitudinal Associations Between Handgrip Strength and Cardiovascular Disease Biomarkers Among Middle-Aged to Older Adults: A Project FRONTIER Study. J Aging Phys Act. 2020 Jan 1;28(1):9-17. doi: 10.1123/japa.2018-0399.
  14. Vijayan M, Alamri FF, Al Shoyaib A, Karamyan VT, Reddy PH. Novel miRNA PC-5P-12969 in Ischemic Stroke. Mol Neurobiol. 2019; 56(10):6976-6985. doi: 10.1007/s12035-019-1562-x.
  15. Kumar S, Reddy PH. A New Discovery of MicroRNA-455-3p in Alzheimer's Disease. J Alzheimers Dis. 2019;72(s1):S117-S130. doi: 10.3233/JAD-190583.
  16. Kumar S, Reddy AP, Yin X, Reddy PH. Novel MicroRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(9):2428-2440. doi: 10.1016/j.bbadis.2019.06.006.
  17. Tamarai K, Bhatti JS, Reddy PH. Molecular and cellular bases of diabetes: Focus on type 2 diabetes mouse model-TallyHo. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2276-2284. doi: 10.1016/j.bbadis.2019.05.004.
  18. Oliver D, Reddy PH. Dynamics of Dynamin-Related Protein 1 in Alzheimer's Disease and Other Neurodegenerative Diseases. Cells. 2019; 8(9). pii: E961. doi: 10.3390/cells8090961.
  19. Ramasubramanian B, Reddy PH. Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer's Disease? J Alzheimers Dis. 2019. doi: 10.3233/JAD-190613.
  20. Hegde V, Vijayan M, Kumar S, Akheruzzaman M, Sawant N, Dhurandhar NV, Reddy PH. Adenovirus 36 improves glycemic control and markers of Alzheimer's disease pathogenesis. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(11):165531. doi: 10.1016/j.bbadis.2019.08.007
  21. Gamage S, Peddibhotla S, Reddy PH, Dhurandhar NV, Hegde V. Improvement in Glycemic Control in Mice of Different Age Groups. Exp Clin Endocrinol Diabetes. 2019. doi: 10.1055/a-0961-7804.
  22. George EK, Reddy PH. Can Healthy Diets, Regular Exercise, and Better Lifestyle Delay the Progression of Dementia in Elderly Individuals? J Alzheimers Dis. 2019;72(s1):S37-S58. doi: 10.3233/JAD-190232.
  23. Reddy PH, Oliver DM. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease. Cells. 2019;8(5). pii: E488. doi: 10.3390/cells8050488.

Click here for a complete list of Dr. Reddy's publications.